HMG CoA reductase inhibitor-induced muscle toxicity: Risks, monitoring, and management

Formulary

Volumn 37, Issue 11, 2002, Pages 583-588

  White, C Michael ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CREATINE KINASE; CYTOCHROME P450 3A4; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN;

AGE; ARTICLE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; PATHOPHYSIOLOGY; RHABDOMYOLYSIS;

EID: 0036846548     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Transcripts of the Joint Meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Advisory Committee, July 13 and 14, 2000. Available at http://www.fda.gov/ohrms/dockets/ac/cder00.htm #Nonprescription. Accessed September 1, 2002.
2. Berkow R, ed. Chapter 21: Special subjects. In: The Merck Manual, 16th Ed. Rahway, NJ: Merck and Co; 1992:2573-91.
3. Woodrow G, Brownjohn AM, Tumey JH. The clinical and biochemical features of acute renal failure due to rhabdomyolysis. Renal Failure 1995;17:467-74.
4. Veenstra J, Srnit WM, Krediet RT, Arisz L. Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis. Nephrol Dial Transplant 1994;9:637-41.
5. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72.
6. Viswewaran P, Guntupalli J. Rhabdomyolysis. Crit Care Clin 1999;15:415-28.
7. White CM. An evaluation of the CYP3A4 drug interactions with HMG CoA reductase inhibitors. Formulary 2000;35:343-52.
8. Wiener SL. Chapter 44: Acute inguinal, trochanteric, pubic, and thigh pain. In: Differential Diagnosis of Acute Pain. New York: Mcgraw Hill; 1993: 571-41.
9. Orgog GJ, Wasserberger J. Chapter 12: Medical toxicology in critical care medicine. In: Grenvik A, ed. Textbook of Critical Care, 4th Ed. Philadelphia, PA: WB Saunders Co; 2000:160-90.
10. Koppel C. Clinical features, pathogenesis and management of drug-induced rhabdomyolysis. Med Toxicol Adverse Drug Exper 1989;4:108-26.
11. Lane RJ, Mastaglia FL. Drug induced myopathies in man. Lancet 1978;4:562-6.
12. Curry SC, Chang D, Connor D. Drug- and toxin-induced rhabdomyolysis. Ann Emerg Med 1989;18:1068-84.
13. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis [letter]. N Engl J Med 2002;346:540-1.
14. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-95.
15. White CM. Pharmacologic and pharmacokinetc aspects of rosuvastatin. J Clin Pharmacol 2002;42:963-70.
16. McTavish D, Sorkin EM. Pravastatin: A review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs 1991;42:65-89.
17. Negre-Aminou P, Van Vliet AK, Van Erck M, et al. Inhibition of proliferation of human smooth muscle cells by various HMg CoA reductase inhibitors: Comparison with other human cell types. Biochemica et Biophysica Acta 1997;1345:259-68.
18. Pearson TA, Lauora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP). Arch Intern Med 2000;160:459-67.
19. Raiteri M, Arnaboldi L, McGeady P, et al. Pharmacological control of the melvalonate pathway: Effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 1997;281:1144-53.
20. Zocor [Package Insert]. Whitehouse Station, NJ: Merck & Co, Inc; May 2002.
21. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin PharmacolTher 1998;63:332-41.
22. United States Pharmacopeial Convention. USP DI Drug Information for the Health Care Professional, 22nd Ed. Micromedex, Inc. Englewood, CO, 2002.
23. FDA asks AstraZeneca to provide more data for rosuvastatin. HeartWire August 7, 2002. Available at theheart.org. Accessed September 9, 2002.
24. Shepherd, J, Hunninghake D, Harris S, Hutchinson H, Pears J. A review of the safety profile of rosuvastatin in an international phase II/III clinical trial program, Paper presented at the XIV International Symposium on Drugs Affecting Lipid Metabolism, September 9-12, 2001: NewYork.
25. AstraZeneca Crestor NDA includes rhabdomyolysis reports at highest dose. The Pink Sheet 2001;63(50):21.
26. AstraZeneca Crestor Plan: Drop 80 mg, submit lower-dose data in Q1. The Pink Sheet 2002;64(32):27.
27. Ichihara K, Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 2002;359:2195-7.
28. Talbert RL. Chapter 19: Hypertipidemia. In: Dipiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach, 4th Ed. Stamford, CT: Appleton & Lange; 1999:350-73.
29. Walverens PA, Greene C, Frerman FE. Lovastatin, isoprenes, and myopathy [letter]. Lancet 1989;2:1097-8.
30. Maher VM, Pappu A, Elingworth DR, Thompson GR. Plasma melalonate response in lovastatin-related myopathy [letter]. Lancet 1989;2:1098.
31. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996;31:348-71.
32. Laaksonsen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995;57:62-6.
33. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77:851-4.
34. Witztum JL. Chapter 36: Drugs used in the treatment of hyperlipoproteinemias. In: Hardman JG, Limbird LE, eds. Goodmans & Gilman's The harmacologic Basis of Therapeutics, 9th Ed. New York: McGraw-Hill; 1996:875-87.
35. Thompson PD, Gadeleta PA, Yurgalevitch SM, et al. The effects of exercise and lovastatin on serum creatine kinase activity. Metabolism 1991;40:1333-6.
36. Thompson PD, Zmuda JM, Domalik LJ, et al. Lovastatin increases exercise induced skeletal muscle injury. Metabolism 1997;46:1206-10.
37. Evans WJ, Cannon JG. The metabolic effects of exercise induced muscle damage. Exer Sport Sci Rev 1991;19:99-125.
38. Caron MF, White CM. Evaluation of antihyperlipidemic properties of dietary supplements. Pharmacotherapy 2001;21:481-7.